Dogwood Therapeutics Inc (DWTX) News & EventsDWTXNews & EventsDogwood Therapeutics Inc

Dogwood Enrolls First 200 Patients in HAL-CINP Phase 2b Trial

Dogwood announced it has enrolled the first 200 patients in its ongoing HAL-CINP Phase 2b trial. HAL-CINP remains on track for top-line data readout from the four-week study in the fall of 2026.

Dogwood Therapeutics Commences Halneuron Pain Study

Dogwood Therapeutics announced commencement of a new Halneuron chemotherapy induced neuropathic pain phase 2b extension study. "Neuropathic pain is a difficult to treat chronic condition, as evidenced by the five-year mean duration of symptoms for the patients enrolling in our current Halneuron CINP Phase 2b trial," said R. Michael Gendreau, chief medical officer of Dogwood. "This new 12-week long term extension will generate important additional data on how best to optimize Halneuron maintenance treatment for our planned Phase 3 program and potential commercialization".

Dogwood Partners with PRIDCor for $100M Development Agreement

Dogwood announced a global development and commercialization partnership with PRIDCor Therapeutics, a clinical-stage biopharmaceutical company developing antiviral therapies for infection-associated chronic illnesses including Long-COVID, for Dogwood's anti-viral candidates, IMC-1 and IMC-2. The agreement includes potential payments of up to $100M to Dogwood and its current and former shareholders. Dogwood Therapeutics previously announced its intention to explore partnership opportunities to advance its combination antiviral drug candidates and shift its primary focus to advancing its NaV 1.7 inhibitor, Halneuron, to treat both chronic and acute pain conditions. Dogwood subsequentially in-licensed SP16, administered via intravenous formulation, as a complement to its lead asset Halneuron. Consistent with its prior announcement, Dogwood has entered into an agreement with PRIDCor pursuant to which PRIDCor will be fully responsible for financing and executing future development, commercialization and intellectual property maintenance for both IMC-1 and IMC-2. In exchange, Dogwood is entitled to a tiered royalty on net sales of up to 15% upon commercialization of IMC-1 or IMC-2. Further, Dogwood is entitled to 9% of all future capital raised by PRIDCor to advance IMC-1 or IMC-2, as well as future PRIDCor partnership-related development and regulatory payments associated with IMC-1 or IMC-2. Potential payments to Dogwood under the development partnership are capped at $100M.